MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

Author's Avatar
Jan 05, 2023
  • Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( 84.9 million)
  • Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 million
  • Preliminary unaudited financial liability from the collaboration with Incyte of approximately € 220 million which represents a reduction of € 360 million